IMR Press / RCM / Volume 4 / Issue S4 / pii/1561439365997-1780916919

Reviews in Cardiovascular Medicine (RCM) is published by IMR Press from Volume 19 Issue 1 (2018). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by IMR Press on as a courtesy and upon agreement with MedReviews, LLC.

Open Access Review
Combining Natriuretic Peptides and Necrosis Markers in the Assessment of Acute Coronary Syndromes
Show Less
1 Donald W. Reynolds Cardiovascular Clinical Research Center, University of Texas Southwestern Medical Center, Dallas, TX
2020 The TIMI Study Group and Division of Cardiology, Brigham and Women's Hospital, Boston, MA
Rev. Cardiovasc. Med. 2003, 4(S4), 37–46;
Published: 20 July 2003
Management of patients with acute coronary syndromes (ACS) is becoming more complex as the array of treatment options available to patients and physicians continues to expand. Cardiac biomarkers play an important role in risk stratification in ACS, and results of cardiac biomarker tests can be used to help guide choices between alternative therapies. In addition to biomarkers of myocyte necrosis, markers of neurohormonal activation, such as B-type natriuretic peptide (BNP), provide important prognostic information in ACS. In the future, multimarker strategies that incorporate panels of cardiac biomarkers are likely to be used for risk stratification and for pathophysiologyguided treatment in patients with ACS. 
Acute coronary syndromes
B-type natriuretic peptide
Cardiac troponins
C-reactive protein
Creatine kinase
Back to top